Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Sarepta Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Sarepta Therapeutics, Inc.’s stock price such as:

• Sarepta Therapeutics, Inc.’s current stock price and volume
• Why Sarepta Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for SRPT from analysts
• SRPT’s stock price momentum as measured by its relative strength

About Sarepta Therapeutics, Inc. (SRPT)

Before we jump into Sarepta Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children’s Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Sarepta Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc.’s Stock Price as of Market Close

As of December 11, 2025, 4:00 PM, CST, Sarepta Therapeutics, Inc.’s stock price was $21.750.

Sarepta Therapeutics, Inc. is down 2.03% from its previous closing price of $22.200.

During the last market session, Sarepta Therapeutics, Inc.’s stock traded between $20.760 and $21.960. Currently, there are approximately 100.24 million shares outstanding for Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Sarepta Therapeutics, Inc. Stock Price History

Sarepta Therapeutics, Inc.’s (SRPT) price is currently up 1.92% so far this month.

During the month of December, Sarepta Therapeutics, Inc.’s stock price has reached a high of $23.000 and a low of $19.370.

Over the last year, Sarepta Therapeutics, Inc. has hit prices as high as $129.840 and as low as $10.415. Year to date, Sarepta Therapeutics, Inc.’s stock is down 82.11%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Sarepta Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 10, 2025, there were 4 analysts who downgraded Sarepta Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Sarepta Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Sarepta Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Sarepta Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Sarepta Therapeutics, Inc. (SRPT) by visiting AAII Stock Evaluator.

Relative Price Strength of Sarepta Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 10, 2025, Sarepta Therapeutics, Inc. has a weighted four-quarter relative price strength of -20.00%, which translates to a Momentum Score of 10 and is considered to be Very Weak.

Want to learn more about how Sarepta Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Sarepta Therapeutics, Inc. Stock Price: Bottom Line

As of December 11, 2025, Sarepta Therapeutics, Inc.’s stock price is $21.750, which is down 2.03% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Sarepta Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.